Published in Pharma Investments, Ventures and Law Weekly, May 7th, 2006
The net loss for the 12-month fiscal period ended December 31, 2005 was $19.2 million, or $0.49 loss per share, compared to a net loss of $8.1 million, or $0.22 loss per share, for the 6-month fiscal transition period ended December 31, 2004. Operating expenses totaled $18.3 million for the 12-month fiscal period ended December 31, 2005 as compared to $7.4 million for the 6-month fiscal transition period ended December 31, 2004.
Cash, cash...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.